Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ortetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.50 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.50 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.46 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.46 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.46 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.46 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.46 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.46 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.46 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.46 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.46 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ortetamine SCHEMBL16737004 | 1.00 | TAAR1 (0.50) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL29388899 | 0.98 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL27660676 | 0.98 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL3460028 | 0.98 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL209899 | 0.98 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL42180 | 0.98 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL4381142 | 0.88 | SLC6A4 (0.70) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL2857779 | 0.84 | SLC6A2 (0.61) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Hydrochloric Acid SCHEMBL27316517 | 0.83 | SOS2 (0.51) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL27703116 | 0.81 | CYP2D6 (0.44) | TAAR1SLC6A2SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104168766-A | Methods and compositions for treating or preventing attention deficit hyperactivity disorder | OMTHERA PHARMACEUTICALS INC | 2014-11-26 | — | — | CN | claimed |
| CN-101969930-A | Misuse preventative, controlled release formulation | LABOPHARM INC | 2011-02-09 | — | — | CN | claimed |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | claimed |
| WO-2004103283-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CENTRAL NERVOUS SYSTEM STIMULANT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| US-20240033258-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE (US) | 2024-02-01 | — | — | US | disclosed |
| US-20220202791-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE | 2022-06-30 | — | — | US | disclosed |
| US-11179377-B2 | Pharmaceutical compositions and uses thereof | EMBERA NEUROTHERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200360400-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION, PSYCHIATRIC DISORDERS, AND NEURODEGENERATIVE DISEASE | EMBERA NEUROTHERAPEUTICS, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200054615-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EMBERA NEUROTHERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| CN-110494133-A | The prevention of ampa receptor related disease and/or therapeutic agent | PUBLIC UNIV CORP YOKOHAMA CITY UNIV | 2019-11-22 | — | — | CN | disclosed |
| CN-110267949-A | SGC stimulant | 塞科里昂医疗股份有限公司 | 2019-09-20 | — | — | CN | disclosed |
| US-20190275058-A1 | COMPOSITIONS AND METHODS FOR TREATING ADDICTION OR SUBSTANCE USE DISORDERS | EMBERA NEUROTHERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
| EP-0946151-A1 | ASCENDING-DOSE DOSAGE FORM | ALZA CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998044158-A1 | SIMULTANEOUS COLLECTION OF DNA AND NON-NUCLEIC ANALYTES FROM ORAL FLUIDS | EPITOPE, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998023263-A1 | ASCENDING-DOSE DOSAGE FORM | ALZA CORPORATION (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5703048-A | HEPATOCYTE GROWTH FACTOR | GENENTECH, INC, (US) | 1997-12-30 | — | — | US | disclosed |
| US-5654404-A | Protection against liver damage by HGF | GENENTECH, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0661993-B1 | PROTECTION AGAINST LIVER DAMAGE BY HGF | GENENTECH INC (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0661993-A1 | PROTECTION AGAINST LIVER DAMAGE BY HGF. | GENENTECH INC (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994006456-A1 | PROTECTION AGAINST LIVER DAMAGE BY HGF | GENENTECH, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179377-B2 | Pharmaceutical compositions and uses thereof | OPRM1, CYP2C19, COMT | SLC6A2 2142/4885SLC6A4 1310/4885SLC6A3 969/4885 |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | GAP43, PTGS2, CNR2 | SLC6A2 67/4885SLC6A4 278/4885SLC6A3 177/4885 |
| US-20200054615-A1 | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | OPRM1, CYP2C19, COMT | SLC6A2 2142/4885SLC6A4 1310/4885SLC6A3 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.